Open App
Company / Named in our posts

Liminatus.

Follow Liminatus

Liminatus is a pre-clinical stage, single-asset biopharmaceutical company developing novel cancer therapies that exploit the body’s immune system.[1]

01Deal
01

Deals on Carrywatch

Every deal that names Liminatus, and its role in each.

Iris / Liminatus

Iris and Liminatus complete business combination

See deal details
02

Deal Web

Liminatus and 0 firms it shares a posted deal with, and the path to any other firm.

03

Financials

1 fiscal year of figures as Liminatus reported them.

04

News

Loading headlines.

05

Sources

As of 25 Oct 2026.

  1. 01
    Exhibit 99.2 — Liminatus Pharma, LLC Financial Statements

    U.S. Securities and Exchange Commission · Researched 25 Oct 2026

  2. 02
    Form 8-K — Liminatus Pharma, Inc.

    U.S. Securities and Exchange Commission · Researched 25 Oct 2026

Deal posts naming Liminatus:

  1. P01